Sunil Verma,David Miles,Luca Gianni,Ian E. Krop,Manfred Welslau,José Baselga,Mark D. Pegram,Do‐Youn Oh,Véronique Dièras,Ellie Guardino,Fang Ting Liang,Michael W. Lu,Steven R. Olsen,Kim T. Blackwell
Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)–targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1. The antibody and the cytotoxic agent are conjugated by means of a stable linker.